Reinach, Switzerland

Cornelius Stephan Harlacher

USPTO Granted Patents = 3 

 

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2021-2022

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Cornelius Stephan Harlacher: Innovator in Pharmaceutical Chemistry

Introduction

Cornelius Stephan Harlacher is a notable inventor based in Reinach, Switzerland. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of polymorphic forms of specific compounds. With a total of 3 patents to his name, Harlacher continues to push the boundaries of innovation in drug formulation.

Latest Patents

Harlacher's latest patents include two related to the preparation of polymorphic forms of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide. The first patent describes a method for producing Form A of this compound, which is crucial for pharmaceutical applications. The second patent outlines a process for preparing Form B of the same compound, further expanding the potential uses of this innovative drug formulation.

Career Highlights

Cornelius Harlacher is currently associated with Mereo Biopharma 1 Limited, where he applies his expertise in pharmaceutical development. His work focuses on enhancing the efficacy and stability of drug formulations, which is vital for improving patient outcomes.

Collaborations

Harlacher collaborates with talented professionals in his field, including Osama Suleiman and Lucia Romero Perez. These partnerships foster a creative environment that encourages the exchange of ideas and advancements in pharmaceutical research.

Conclusion

Cornelius Stephan Harlacher is a distinguished inventor whose work in pharmaceutical chemistry has led to significant advancements in drug formulation. His contributions, particularly in the development of polymorphic forms, highlight the importance of innovation in the healthcare industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…